IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

Jingjing Zhao; Sarah Turpin-Nolan; Mark A. Febbraio

doi:10.1016/j.cyto.2021.155549

IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

Jingjing Zhao, Sarah Turpin-Nolan, Mark A. Febbraio

Drug Discovery Biology

Research output: Contribution to journal › Review Article › Research › peer-review

8 Citations (Scopus)

Abstract

Metabolic disease is highly prevalent. Here we discuss the therapeutic utility of using gp130 receptor ligands as a therapeutic strategy to treat metabolic disease.

Original language	English
Article number	155549
Number of pages	7
Journal	Cytokine
Volume	144
DOIs	https://doi.org/10.1016/j.cyto.2021.155549
Publication status	Published - Aug 2021

Keywords

Gp130 ligands
IL-6
Metabolic disease

Access to Document

10.1016/j.cyto.2021.155549Licence: CC BY

Cite this

@article{889a70b4e0ba47d3920a38349046405c,

title = "IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases",

abstract = "Metabolic disease is highly prevalent. Here we discuss the therapeutic utility of using gp130 receptor ligands as a therapeutic strategy to treat metabolic disease.",

keywords = "Gp130 ligands, IL-6, Metabolic disease",

author = "Jingjing Zhao and Sarah Turpin-Nolan and Febbraio, {Mark A.}",

note = "Funding Information: MAF is supported by a Senior Principal Research Fellowship (APP1116936) and an Investigator Award (APP1194141) by National Health & Medical Research Council of Australia. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = aug,

doi = "10.1016/j.cyto.2021.155549",

language = "English",

volume = "144",

journal = "Cytokine",

issn = "1096-0023",

publisher = "Academic Press",

}

TY - JOUR

T1 - IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

AU - Zhao, Jingjing

AU - Turpin-Nolan, Sarah

AU - Febbraio, Mark A.

N1 - Funding Information: MAF is supported by a Senior Principal Research Fellowship (APP1116936) and an Investigator Award (APP1194141) by National Health & Medical Research Council of Australia. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/8

Y1 - 2021/8

N2 - Metabolic disease is highly prevalent. Here we discuss the therapeutic utility of using gp130 receptor ligands as a therapeutic strategy to treat metabolic disease.

AB - Metabolic disease is highly prevalent. Here we discuss the therapeutic utility of using gp130 receptor ligands as a therapeutic strategy to treat metabolic disease.

KW - Gp130 ligands

KW - IL-6

KW - Metabolic disease

UR - http://www.scopus.com/inward/record.url?scp=85105353553&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2021.155549

DO - 10.1016/j.cyto.2021.155549

M3 - Review Article

AN - SCOPUS:85105353553

SN - 1096-0023

VL - 144

JO - Cytokine

JF - Cytokine

M1 - 155549

ER -

IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

Abstract

Keywords

Access to Document

Other files and links

Development of novel therapies to treat obesity related metabolic diseases

Towards a better understanding of the health benefits of physical activity: designing exercise mimetic for the treatment of disease

Cite this

IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

Abstract

Keywords

Access to Document

Other files and links

Projects

Development of novel therapies to treat obesity related metabolic diseases

Towards a better understanding of the health benefits of physical activity: designing exercise mimetic for the treatment of disease

Cite this